Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

  • Webcast Image Webcast
    X Q3 2017 Cytokinetics, Inc. Earnings Conference Call
    Oct 26, 2017 at 4:30 PM EDT

    Q3 2017 Cytokinetics, Inc. Earnings Conference Call
    Oct 26, 2017 at 4:30 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

03/15/17
( FY )
ALS

ALS

03/15/17
( FY )
SMA

SMA

03/15/17
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Announce Third Quarter Results on October 26, 2017
SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report third quarter results on October 26, 2017 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a
Toggle Summary Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Company Earns $10 Million Milestone Payment from Amgen SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that the first patient has been dosed in Japan in GALACTIC-HF ( G lobal A pproach to L owering A dverse C ardiac Outcomes
Toggle Summary Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting
Effects of Omecamtiv Mecarbil Were Similar in Patients with Ischemic and Non-Ischemic Heart Failure SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin
Toggle Summary Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting
SOUTH SAN FRANCISCO, Calif. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF ( C hronic O ral S tudy of M yosin Activation to I ncrease C ontractility in H eart F ailure), a Phase 2 trial evaluating omecamtiv mecarbil in